We report a 23-year-old woman who presented with generalized scaly erythematous rash predominately on the upper trunk and hemorrhagic stomatitis. The histopathologic and immunopathologic findings were consistent with the diagnosis of paraneoplastic pemphigus. Castleman’s tumor was diagnosed with computed tomography and exploratory laparotomy. A partial clinical improvement was observed after complete tumor removal and intravenous immunoglobulin administration. However, the patient died as a result of septicemia.

Paraneoplastic pemphigus (PNP) is an uncommon autoimmune blistering disease characterized by intractable stomatitis, polymorphous cutaneous eruption, and neoplasm. It was first described by Anhalt et al. in 1990 [1]. The exact pathogenesis of PNP is still unclear. However, the tumor may cause immune dysregulation leading to autoantibody production targeting epidermal cell surface antigens such as desmoplakin I (250 kD), bullous pemphigoid antigen I (230 kD), desmoplakin II (210 kD), envoplakin (210 kD), periplakin (190 kD), plectin (500 kD), and a 170-kD protein. This condition presents most frequently between the age of 45 and 70 years, but also occurs in the younger age group. Apart from skin and oral mucosa involvement, PNP can affect the gastrointestinal and respiratory tract epithelium. The prognosis is generally poor. Progression of malignant tumors may be inevitable. Moreover, sepsis complications and bronchiolitis obliterans are frequent causes of mortality in PNP.

A 23-year-old female was referred to our university-based hospital with generalized skin rash and oral ulcer for 6 weeks. The rash first appeared on the trunk and gradually progressed to involve all extremities as well as the face. There was no history of recent upper respiratory tract infection. She had no underlying skin disease or systemic disease and did not take any medication. She was treated with intravenous dexamethasone 20 mg daily, intravenous acyclovir, and oral azithromycin for 5 days by a local dermatologist without clinical improvement.

On examination, temperature was 37.3°C, pulse 92 beats per minute, blood pressure 130/70 mm Hg, and respiratory rate 20 breaths per minute. Dermatologic examination showed generalized scaly erythema with multiple foci of atypical targetoid lesions on the trunk and all extremities as well as the face. Bilateral conjunctival injection, scaly hemorrhagic crusted erosion on both upper and lower lips, as well as mild erosion on bilateral buccal mucosa and genital site were noted (Fig. 1). Lymph nodes were impalpable. The remaining examinations were unremarkable.

Fig. 1.

Hemorrhagic crust, scaly erosion on the lips, and generalized erythroderma with some foci of atypical target lesions on the face, trunk, and upper extremities (a, b).

Fig. 1.

Hemorrhagic crust, scaly erosion on the lips, and generalized erythroderma with some foci of atypical target lesions on the face, trunk, and upper extremities (a, b).

Close modal

A 4-mm punch biopsy was performed on a lesion of the chest. Routine histopathology demonstrated superficial perivascular infiltration (predominately consisting of lymphocytes and eosinophils), mild epidermal hyperplasia, basal vacuolization, exocytosis, scattered necrotic keratinocyte, as well as prominent melanophages (Fig. 2). Direct immunofluorescence study showed intercellular deposition of IgG resembling chicken wire feature and linear basement membrane zone staining with IgG and C3 (Fig. 3).

Fig. 2.

Superficial perivascular infiltration (predominately consisting of lymphocytes and eosinophils), mild epidermal hyperplasia, basal vacuolization, exocytosis, scattered necrotic keratinocytes, and prominent melanophages. Hematoxylin-eosin, original magnification ×400.

Fig. 2.

Superficial perivascular infiltration (predominately consisting of lymphocytes and eosinophils), mild epidermal hyperplasia, basal vacuolization, exocytosis, scattered necrotic keratinocytes, and prominent melanophages. Hematoxylin-eosin, original magnification ×400.

Close modal
Fig. 3.

Direct immunofluorescent study showed intercellular deposition of IgG resembling chicken wire feature and linear basement membrane zone staining with IgG (a) and C3 (b).

Fig. 3.

Direct immunofluorescent study showed intercellular deposition of IgG resembling chicken wire feature and linear basement membrane zone staining with IgG (a) and C3 (b).

Close modal

Blood samples for indirect immunofluorescence test disclosed circulating IgG autoantibodies directed against transitional epithelial cells of rat bladder. Anti-desmoglein 1 and anti-desmoglein 3 via the enzyme-linked immunosorbent assay technique were 47.97 U/mL and >200 U/mL (normal <20 U/mL), respectively. Anti-BP180 was >200 RU/mL (normal <20 RU/mL) and anti-BP230 was negative. Herpes simplex virus type 1 and 2 DNA, Venereal Disease Research Laboratory, Treponema pallidum hemagglutination assay, as well as Mycoplasma titer were all negative. We were unable to perform immunoblotting, but given the clinical, histopathologic, as well as direct and indirect immunofluorescence results, the diagnosis was consistent with PNP. Computed tomography with contrast of the chest and abdomen revealed a 6.7 × 5.5 cm, markedly enhancing oval-shaped structure at the left para-aortic region surrounded by dilated vessels. According to the computed tomographic findings, a provisional diagnosis of Castleman’s disease (CD) was made.

The patient was treated with intravenous immunoglobulin (IVIG) 2 g/kg/day over 5 consecutive days and surgical removal of the tumor. The pathologic findings were compatible with hyaline-vascular type CD. Although there was substantial improvement in the truncal lesions 10 days after IVIG administration, the lesions on acral area and the oral lesions were refractory to treatment. Two weeks after the complete 5-day course of IVIG, the patient died as a result of Staphylococcus and Acinetobacter septicemia.

Varied morphologic presentations of PNP have been described, including erythematous macules, flaccid blisters and erosions (pemphigus-like), tense blisters (pemphigoid-like), erythema multiforme-like lesions, lichenoid eruptions (lichen planus-like), and graft-versus-host-like eruptions [2-4]. However, intractable hemorrhagic stomatitis is typically reported as the hallmark feature of this disorder. In adult patients, the three most common neoplasm associated with PNP were non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and CD [5]. However, Ohzono et al. [6] described malignant solid tumor as one of the most common neoplasms associated with PNP. Nearly three-fourths of CD are found in the mediastinum, followed by the retroperitoneal regions and pelvis [7, 8]. CD, discovered by Benjamin Castleman in 1954 [9], originally described a male patient with prolonged fever, nonproductive cough, and mediastinal lymph node hyperplasia resembling thymoma [10]. Three subtypes of CD were later classified. The most common subtype of CD was hyaline-vascular lesion followed by plasmatic subtype and mixed subtype [11]. Corresponding to the finding in our patient, the hyaline-vascular subtype often presents as a solitary mass, albeit the plasmacytoid subtype is characterized by multifocal involvement [12].

The pathophysiologic mechanism of PNP has not been well established. It was hypothesized that lymphoid neoplasms cause immune dysregulation leading to autoantibody production and immune cross-reaction against tumor with the epidermal cell surface antigens [13]. Interferon-gamma, interferon-omega, interleukin-6, and interleukin-12 were also described as playing crucial roles in the pathogenesis [14, 15].

Early total tumor resection is mandatory to achieve resolution of unicentric CD [12, 16]; otherwise, the patients – particularly with erythema multiforme-like skin lesions with extensive skin or mucosal involvement – may face a poor prognosis. The major causes of death included bronchiolitis obliterans followed by sepsis and gastrointestinal bleeding [17]. Systemic corticosteroids, immunosuppressive agents, or IVIG should be commenced as an additional treatment. In patients with severe infection, IVIG should be considered. The reported benefits of IVIG included temporary improvement of skin lesions and prevention of respiratory complications [18, 19]. An antibody titer reduction of up to 43% has been report after 4 weeks of IVIG alone for PNP [20]. This reflects good immunologic response for IVIG. Clinical response and achievement of cutaneous and mucosal improvement, however, may take longer.

Our patient, diagnosed with PNP associated with CD, presented with exfoliative dermatitis with some features of atypical target lesions. To the best of our knowledge, exfoliative erythroderma is an exceedingly rare presentation of PNP. Dermatopathologic study together with immunopathology plays a crucial role in achieving the accurate diagnosis of PNP, allowing prompt management for this fatal disease. Further study focusing on pathogenesis with targeted therapy remains still a glimmer of hope for a treatment with better outcomes.

The authors thank Dr. Poonkiat Suchonwanit and Dr. Pholawat Tingpej for their help in the preparation of illustrations and for language editing.

The authors have no ethical conflicts to disclose. The patient gave written informed consent for publication of his case (including publication of images). The study was done according to the Declaration of Helsinki.

The authors have no conflicts of interest to declare.

None.

T. Sirikham and W. Tawanwongsri collected the data and wrote the initial manuscript draft. S. Rutnin wrote the pathologic description and manuscript. K. Chanprapaph wrote the manuscript and did language editing. V. Vachiramon evaluated and revised the manuscript and is the corresponding author. All authors provided critical feedback and contributed to the final version of the manuscript.

1.
Anhalt
GJ
,
Kim
SC
,
Stanley
JR
,
Korman
NJ
,
Jabs
DA
,
Kory
M
, et al
Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia
.
N Engl J Med
.
1990
Dec
;
323
(
25
):
1729
35
.
[PubMed]
0028-4793
2.
Tirado-Sanchez
A
,
Bonifaz
A
: Paraneoplastic Pemphigus. A Life-Threatening Autoimmune Blistering Disease. Actas dermo-sifiliograficas
2017
;108:902-910.
3.
Frew
JW
,
Murrell
DF
.
Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis
.
Dermatol Clin
.
2011
Jul
;
29
(
3
):
419
25
.
[PubMed]
0733-8635
4.
Nguyen
VT
,
Ndoye
A
,
Bassler
KD
,
Shultz
LD
,
Shields
MC
,
Ruben
BS
, et al
Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus
.
Arch Dermatol
.
2001
Feb
;
137
(
2
):
193
206
.
[PubMed]
0003-987X
5.
Kaplan
I
,
Hodak
E
,
Ackerman
L
,
Mimouni
D
,
Anhalt
GJ
,
Calderon
S
.
Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations
.
Oral Oncol
.
2004
Jul
;
40
(
6
):
553
62
.
[PubMed]
1368-8375
6.
Ohzono
A
,
Sogame
R
,
Li
X
,
Teye
K
,
Tsuchisaka
A
,
Numata
S
, et al
Clinical and immunological findings in 104 cases of paraneoplastic pemphigus
.
Br J Dermatol
.
2015
Dec
;
173
(
6
):
1447
52
.
[PubMed]
0007-0963
7.
Keller
AR
,
Hochholzer
L
,
Castleman
B
.
Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations
.
Cancer
.
1972
Mar
;
29
(
3
):
670
83
.
[PubMed]
0008-543X
8.
Bradley
AJ
,
Thomas
NB
,
Sukumar
SA
.
Castles in the air?
Br J Radiol
.
1997
Jul
;
70
(
835
):
767
8
.
[PubMed]
0007-1285
9.
Castleman
B
.
Case records of the Massachusetts General Hospital; weekly clinicopathological exercise 40011
.
N Engl J Med
.
1954
Jan
;
250
(
1
):
26
30
.
[PubMed]
0028-4793
10.
Castleman
B
,
Iverson
L
,
Menendez
VP
.
Localized mediastinal lymphnode hyperplasia resembling thymoma
.
Cancer
.
1956
Jul-Aug
;
9
(
4
):
822
30
.
[PubMed]
0008-543X
11.
Szalat
R
,
Munshi
NC
.
Diagnosis of Castleman Disease
.
Hematol Oncol Clin North Am
.
2018
Feb
;
32
(
1
):
53
64
.
[PubMed]
0889-8588
12.
Soumerai
JD
,
Sohani
AR
,
Abramson
JS
:
Diagnosis and management of Castleman disease.
Cancer control : journal of the Moffitt Cancer Center
2014
;21:266-278.
13.
Kartan
S
,
Shi
VY
,
Clark
AK
,
Chan
LS
.
Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment
.
Am J Clin Dermatol
.
2017
Feb
;
18
(
1
):
105
26
.
[PubMed]
1175-0561
14.
Meager
A
,
Wadhwa
M
,
Dilger
P
,
Bird
C
,
Thorpe
R
,
Newsom-Davis
J
, et al
Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis
.
Clin Exp Immunol
.
2003
Apr
;
132
(
1
):
128
36
.
[PubMed]
0009-9104
15.
Biondi
A
,
Rossi
V
,
Bassan
R
,
Barbui
T
,
Bettoni
S
,
Sironi
M
, et al
Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia
.
Blood
.
1989
Apr
;
73
(
5
):
1279
84
.
[PubMed]
0006-4971
16.
Wong
RS
:
Unicentric Castleman Disease.
Hematology/Oncology Clinics
2018
;32:65-73.
17.
Leger
S
,
Picard
D
,
Ingen-Housz-Oro
S
,
Arnault
JP
,
Aubin
F
,
Carsuzaa
F
, et al
Prognostic factors of paraneoplastic pemphigus
.
Arch Dermatol
.
2012
Oct
;
148
(
10
):
1165
72
.
[PubMed]
0003-987X
18.
Wang
J
,
Zhu
X
,
Li
R
,
Tu
P
,
Wang
R
,
Zhang
L
, et al
Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China
.
Arch Dermatol
.
2005
Oct
;
141
(
10
):
1285
93
.
[PubMed]
0003-987X
19.
Nanda
M
,
Nanda
A
,
Al-Sabah
H
,
Dvorak
R
,
Alsaleh
QA
.
Paraneoplastic pemphigus in association with B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone
.
Int J Dermatol
.
2007
Jul
;
46
(
7
):
767
9
.
[PubMed]
0011-9059
20.
Lolis
M
,
Toosi
S
,
Czernik
A
,
Bystryn
JC
.
Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies
.
J Am Acad Dermatol
.
2011
Mar
;
64
(
3
):
484
9
.
[PubMed]
0190-9622
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.